Cargando…

PD-L1 expression is associated with advanced non-small cell lung cancer

Lung cancer is the most common cause of cancer-associated mortalities worldwide. Novel immunotherapies have been developed to improve the clinical outcomes of non-small cell lung cancer (NSCLC). Antibodies against programmed cell death protein 1 (PD-1) and programmed cell death protein 1 ligand 1 (P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Zhiquan, Mei, Jiandong, Liu, Lunxu, Wang, Guochen, Li, Zuosheng, Hou, Jingpu, Zhang, Qiuyang, You, Zongbing, Zhang, Liu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950525/ https://www.ncbi.nlm.nih.gov/pubmed/27446371 http://dx.doi.org/10.3892/ol.2016.4741

Ejemplares similares

Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer
por: Mo, Zhongfu, et al.
Publicado: (2016)

Prognostic impact of tumor-associated macrophage infiltration in non-small cell lung cancer: A systemic review and meta-analysis
por: Mei, Jiandong, et al.
Publicado: (2016)

Interleukin-17 Indirectly Promotes M2 Macrophage Differentiation through Stimulation of COX-2/PGE2 Pathway in the Cancer Cells
por: Li, Qingli, et al.
Publicado: (2014)

The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time
por: Ma, Junliang, et al.
Publicado: (2010)

Interferon-γ and celecoxib inhibit lung-tumor growth through modulating M2/M1 macrophage ratio in the tumor microenvironment
por: Ren, Fuqiang, et al.
Publicado: (2014)

The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer
por: Dai, Fuqiang, et al.
Publicado: (2010)

Interleukin-17A Differentially Induces Inflammatory and Metabolic Gene Expression in the Adipose Tissues of Lean and Obese Mice
por: Qu, Yine, et al.
Publicado: (2016)

Patterns of treatment failure for PD-(L)1 refractory extensive-stage small cell lung cancer in continued PD-(L)1 treatment
por: Liu, Li, et al.
Publicado: (2023)

Aminomethylphosphonic Acid and Methoxyacetic Acid Induce Apoptosis in Prostate Cancer Cells
por: Parajuli, Keshab R., et al.
Publicado: (2015)

Aminomethylphosphonic acid inhibits growth and metastasis of human prostate cancer in an orthotopic xenograft mouse model
por: Parajuli, Keshab Raj, et al.
Publicado: (2016)

ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer
por: Liu, Zheng, et al.
Publicado: (2020)

Predictive value of pretreatment PD-L1 expression in EGFR-mutant non-small cell lung cancer: a meta-analysis
por: Peng, Zhiyu, et al.
Publicado: (2021)

PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
por: Ji, Mei, et al.
Publicado: (2015)

Risk factors and outcomes of bronchopleural fistula after bronchoplasty in patients with non-small cell lung cancer: a retrospective multivariate analysis
por: Peng, Zhiyu, et al.
Publicado: (2022)

Lung adenocarcinoma initially mimicking localized emphysema
por: Cheng, Jiahan, et al.
Publicado: (2020)

Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma
por: Zhao, Yanjie, et al.
Publicado: (2020)

PD‐1/PD‐L1 Blockade Therapy in Advanced Non‐Small‐Cell Lung Cancer: Current Status and Future Directions
por: Xia, Liliang, et al.
Publicado: (2019)

Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma
por: Leng, Xuefeng, et al.
Publicado: (2021)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy
por: Ali, Wael Abdullah Sultan, et al.
Publicado: (2021)

Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
por: Su, Chaoyue, et al.
Publicado: (2020)

Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors
por: Song, Peng, et al.
Publicado: (2019)

Positive Surgical Margin, HPV Persistence, and Expression of Both TPX2 and PD-L1 Are Associated with Persistence/Recurrence of Cervical Intraepithelial Neoplasia after Cervical Conization
por: Zhang, Hui, et al.
Publicado: (2015)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

AZD5363 Inhibits Inflammatory Synergy between Interleukin-17 and Insulin/Insulin-Like Growth Factor 1
por: Chen, Chong, et al.
Publicado: (2014)

The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer
por: Sheng, Zhixin, et al.
Publicado: (2017)

A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer
por: You, Wei, et al.
Publicado: (2018)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
por: Zhang, Yaxiong, et al.
Publicado: (2018)

Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer
por: Kallergi, Galatea, et al.
Publicado: (2018)

The influence of pharmaceutical care in patients with advanced non-small-cell lung cancer receiving combination cytotoxic chemotherapy and PD-1/PD-L1 inhibitors
por: Kou, Wen, et al.
Publicado: (2022)

Author Correction: Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors
por: Song, Peng, et al.
Publicado: (2020)

What does radiomics do in PD‐L1 blockade therapy of NSCLC patients?
por: Cui, Ruichen, et al.
Publicado: (2022)

The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
por: Tang, Yanna, et al.
Publicado: (2015)

Anti‐PD1 or anti‐PD‐L1 antibodies alone or in combination with chemotherapy first‐line treatment of advanced non‐small cell lung cancer
por: Zhang, Xuexia, et al.
Publicado: (2022)

Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer
por: Sun, Yuxin, et al.
Publicado: (2020)

PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer
por: Larsen, Trine Vilsbøll, et al.
Publicado: (2019)

High SHP2 expression determines the efficacy of PD‐1/PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer
por: Feng, Hui‐Bo, et al.
Publicado: (2021)

Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer
por: Cui, Pengfei, et al.
Publicado: (2020)

Modifying factors of PD‐L1 expression on tumor cells in advanced non‐small‐cell lung cancer
por: Avilés‐Salas, Alejandro, et al.
Publicado: (2022)

Targeting PD-L1 in non-small cell lung cancer using CAR T cells
por: Liu, Ming, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g9vq9qu2uv86ac9mohejb9koqm